<div id="readability-page-1"><div><p><span>Tessari Eben, Chief Operating Officer of Kiniksa Pharmaceuticals Ltd [KNSA], filed a Form 144 on November 26, 2025 with the Securities and Exchange Commission proposing to sell restricted securities:</span></p><div><table><tbody><tr><td><span>Approximate Date Of Sale</span></td><td><span>11/26/25</span></td></tr><tr><td><span>Shares</span></td><td><span>48,384</span></td></tr><tr><td><span>Broker</span></td><td><span>Charles Schwab &amp; Co Inc</span></td></tr></tbody></table></div><ul><li><span>*</span></li><li><span>Executed pursuant to a prearranged trading plan (10b5-1).</span></li></ul><p><span>Prior to the sale of restricted stock, owners must file a Form 144 with the SEC.  Upon submission of the filing to the SEC the owner is permitted to sell the shares, or any fraction thereof, within 90 days.</span></p><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

KNSA

<p>COO Tessari Eben of Kiniksa Pharmaceuticals Ltd filed a Form 144 with the SEC to sell 48,384 restricted shares on November 26, 2025, through Charles Schwab & Co Inc, under a prearranged trading plan (10b5-1). The sale must occur within 90 days of filing.</p>

COO Tessari Files To Sell 48,384 Of Kiniksa Pharmaceuticals Ltd [KNSA]